UBS Group
MDGL icon

UBS Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

UBS Group’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-571
Closed -$7K – 7952
2015
Q4 		$7K Hold
571
– – ﹤0.01% 7517
2015
Q3 		$35K Hold
571
– – ﹤0.01% 6148
2015
Q2 		$45K Buy
571
+57
+11% +$4.78K ﹤0.01% 6087
2015
Q1 		$35K Hold
514
– – ﹤0.01% 6390
2014
Q4 		$48K Buy
+514
New +$53.1K ﹤0.01% 6527

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group's MDGL Position: Q2 2026 in Review

UBS Group increased its Madrigal Pharmaceuticals (MDGL) stake by 241% in Q2 2026, buying an estimated $145M and bringing the position to 401,708 shares worth $216M. The position accounts for 0.03% of the portfolio, ranked #627.

UBS Group first reported a position in MDGL in Q4 2014 and has held it in 46 quarters since. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • UBS Group held 401,708 shares of Madrigal Pharmaceuticals worth $216M as of Q2 2026.
  • UBS Group bought 283,929 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $145M.
  • Madrigal Pharmaceuticals made up 0.03% of UBS Group's portfolio in Q2 2026, its #627 holding.
  • UBS Group first reported a position in Madrigal Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.